Table 2:

Summary of RANO 2.0 criteria

RANO 2.0 categories
Complete Response (CR) – compare to baseline
disappearance of target and non-target lesions sustained for ≥4 weeks^{^a}
and no new lesions^{^b}
and clinical status is stable or improved
and off corticosteroids (or on physiologic replacement dose)
Partial Response (PR) – compare to baseline
at least 50% decrease in tumor burden with 2D measurements, or 65% with 3D measurements, sustained for ≥4 weeks^{^a}^,^{^e}
and no newly-measurable lesions^{^b}^,^{^c}^,^{^d}
and clinical status is stable or improved
and corticosteroid dose is stable compared to baseline (or on physiologic replacement dose)
Minor Response (MR, only applicable to non-CE disease) – compare to baseline
25% to 50% decrease in tumor burden with 2D measurements, or 40% to 65% with 3D measurements, sustained for ≥4 weeks^{^a}
and no newly-measurable lesions^{^b}^,^{^c}^,^{^d}
and clinical status is stable or improved
and corticosteroid dose is stable compared to baseline (or on physiologic replacement)
Progressive Disease (PD)^{^f} – compare to nadir
at least 25% increase in tumor burden with 2D measurements, or 40% with 3D measurements, with or without confirmation scan after ≥4 weeks^{^g}
or appearance of newly-measurable lesions^{^b}^,^{^c}^,^{^d}
or appearance of leptomeningeal disease
or clinical deterioration not ascribable to steroid dose reduction or other causes apart from the tumor
or failure to return for evaluation as a result of death or clinical deterioration
Stable Disease (SD)
all scenarios that do not meet criteria for CR, PR, MR, or PD.
e.g., stable radiographic findings without clinical deterioration.

Note:—CE indicates contrast-enhancing; CR, complete response; MR, minor response; PD, progressive disease; PsP, pseudoprogression; PR, partial response; SD, stable disease.
↵^a Confirmation scans after ≥4 weeks to confirm durable MR/PR/CR are always required. If confirmed, MR/PR/CR is backdated to the date of preliminary MR/PR/CR. If a patient is lost to follow-up (censored) before confirmation, preliminary CR/PR/MR is considered SD.
↵^b Disregard new non-CE lesions unequivocally ascribable to post-RT.
↵^c Either new measurable lesions or previously non-measurable lesions that became measurable and grew ≥5x≥5 mm.
↵^d For CE-tumors, only CE lesions should be considered.
↵^e In mixed tumors, the assessment should be performed in-parallel for both CE and non-CE components, then combined.
↵^f Corticosteroid dose increase alone does not define PD.
↵^g Confirmation scans for PD can be waived: in CE tumors >3 months after RT completion not treated with agents highly associated with PsP; in the evaluation of non-CE progression in non-CE tumors or mixed tumors.